# Nervgen Pharma Corp.: Form 40-F for the period ended Dec 31, 2025

- Company: [Nervgen Pharma Corp.](/companies/ngen.md) (CIK 1751912)
- Form: 40-F
- Filed: 2026-03-31
- Accepted by EDGAR: Mar 31, 2026, 11:30 ET
- Period: 2025-12-31
- Accession: 0001104659-26-037357
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/tmb-20251231x40f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2025-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Net income | 12 months, 2025-01-01 to 2025-12-31 | −CAD 44.1m | ifrs-full:ProfitLoss |
| Diluted EPS | 12 months, 2025-01-01 to 2025-12-31 | −CAD 0.61 | ifrs-full:DilutedEarningsLossPerShare |
| Basic EPS | 12 months, 2025-01-01 to 2025-12-31 | −CAD 0.61 | ifrs-full:BasicEarningsLossPerShare |
| Operating cash flow | 12 months, 2025-01-01 to 2025-12-31 | −CAD 19.5m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Cash and equivalents | at 2025-12-31 | CAD 22.1m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2025-12-31 | CAD 22.8m | ifrs-full:CurrentAssets |
| Total assets | at 2025-12-31 | CAD 23.2m | ifrs-full:Assets |
| Current liabilities | at 2025-12-31 | CAD 19.7m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2025-12-31 | CAD 19.7m | ifrs-full:Liabilities |
| Shareholders' equity | at 2025-12-31 | CAD 3.5m | ifrs-full:Equity |
| Shares outstanding | at 2025-12-31 | 79,649,257 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1751912/000110465926037357/tmb-20251231x40f.htm

Filed Mar 31, 2026.
Source: SEC EDGAR, the filing index for accession 0001104659-26-037357. Last ingested by Listed: Oct 24, 2026, 15:15 ET. No prices; not investment advice.